SCHEMBL20588781

SCHEMBL20588781

Cc1ccc2c(CC(=O)O)coc2c1Cl

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.73
▸ MAPT P10636 4/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ THRB P10828 4/20 0.49
▸ POLB P06746 1/20 0.49
▸ THRA P10827 2/20 0.46
▸ CLIC1 O00299 1/20 0.46
▸ CXCL8 P10145 1/20 0.46
▸ CLCN2 P51788 1/20 0.46
▸ HPGD P15428 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GLA P06280 1/20 0.43
▸ STING1 Q86WV6 1/20 0.43
▸ TP53 P04637 2/20 0.41
▸ PSMB5 P28074 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20588469 0.84 SMN1; SMN2 (0.59) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL20587880 0.84 SMN1; SMN2 (1.00) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL15211231 0.83 SMN1; SMN2 (0.57) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL20587879 0.82 SMN1; SMN2 (0.73) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL20588968 0.79 SMN1; SMN2 (0.69) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL20587925 0.78 SMN1; SMN2 (0.68) SMN1; SMN2MAPTALOX15THRBTHRA
SCHEMBL9276591 0.77 SMN1; SMN2 (0.75) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL7568303 0.75 SMN1; SMN2 (0.55) SMN1; SMN2MAPTALOX15CXCL8PSMB5
SCHEMBL20588475 0.75 SMN1; SMN2 (0.71) SMN1; SMN2MAPTALOX15THRBPOLB
SCHEMBL15211247 0.73 SMN1; SMN2 (0.46) SMN1; SMN2MAPTALOX15THRBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200223837-A1 BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2020-07-16 — — US disclosed
EP-3638664-A1 BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY European Molecular Biology Laboratory (DE) 2020-04-22 — — EP disclosed
CN-110997664-A Benzofuran amides and heteroaromatic analogs thereof for use in therapy 欧洲分子生物学实验室 2020-04-10 — — CN disclosed
WO-2018229193-A1 BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2018-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200223837-A1 BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY SUCNR1, CBR1, CYP2A13 SMN1; SMN2 1329/4885MAPT 2012/4885ALOX15 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback